Health PR
Day 1 of Mark Henderson’s GLOBALHealthPR Exchange at Spectrum, Washington, D.C.
Since arriving in Washington DC as part of the GLOBALHealthPR Professional Exchange Program, I’ve been privileged to witness a lot of American history, from Capitol Hill (the seat of the United States Congress and legislative branch of the US Federal Government), to The White House (the official residence and principal workplace of the President of…
Read MoreVIVA! clinches Highly Commended in Health Organisations category at QLD PRIA Golden Target Awards
If you’ve ever submitted a state-of-the-art PR campaign into an industry competition, you would fully comprehend the process involved. But the effort can certainly pay off. The 2016 PR industry awards season kicked-off last Friday, September 16 in Brisbane with the Public Relations Institute of Australia’s (PRIA) 40th Golden Target Awards (GTAs). PRIA’s Queensland State…
Read MoreAustralia’s only locally manufactured QIV now TGA approved – August 2, 2016
Australia’s only locally manufactured, quadrivalent seasonal influenza vaccine (QIV) received Therapeutic Goods Administration (TGA) approval on July 15, 2016. Afluria Quad™, Seqirus’ four-strain, inactivated seasonal influenza vaccine, is indicated for people aged 18 years and older.1 The new quadrivalent vaccine will replace the company’s trivalent vaccine (TIV), Fluvax® for the 2017 flu season. Manufactured by…
Read MoreResearchers develop vaccine targeting abnormal proteins that trigger Alzheimer’s – July 16, 2016
A vaccine to prevent the onset of Alzheimer’s disease is a step closer following a breakthrough development that successfully targets the abnormal proteins that trigger the disease. In what is being hailed as the first vaccine of its kind, Flinders University, Adelaide and US researchers contend the vaccine could be used to prevent Alzheimer’s, and…
Read MoreLife-saving drug now available to Australian infants living with HT-1 – June 30, 2016
Australian infants and children living with a rare, inherited genetic disease known as Hereditary Tyrosinaemia Type 1 (HT-1) are now eligible to receive the life-saving treatment, Orfadin (insert chemical compound) under the Life Savings Drug Program (LSDP). In newborns living with the rare, genetic metabolic disorder, the baby lacks the ability to break down the…
Read More